Abbott, Biocompatibles To Initiate Drug-Coated Stent Trial By Year-End
This article was originally published in The Gray Sheet
Executive Summary
Abbott Laboratories expects to begin human clinical trials of a drug-coated stent for in-stent restenosis with partner Biocompatibles by the end of 2001.
You may also be interested in...
Abbott Plays It Safe, Obtains Cordis License For BiodivYsio Launch
Abbott Labs' U.S. launch of British partner Biocompatibles' phosphorylcholine-coated BiodivYsio coronary stent following FDA approval July 5 will not include a rapid-exchange version of the device, according to the company.
Abbott Plays It Safe, Obtains Cordis License For BiodivYsio Launch
Abbott Labs' U.S. launch of British partner Biocompatibles' phosphorylcholine-coated BiodivYsio coronary stent following FDA approval July 5 will not include a rapid-exchange version of the device, according to the company.
Cook, Inc. Coated Stent IDE Clearance Follows J&J/Cordis By One Month
Cook, Inc.' s March 2 investigational device exemption clearance appears to have cut Johnson & Johnson's six to eight-month lead in bringing a drug-eluting stent to the U.S. market by at least half.